Laurus Labs cash flow

Latest FY26

Cash from operations: ₹1,624cr+169.8% on FY25
Capital spending: ₹1,070cr+66.9% on FY25
Free cash flow: ₹554cr−₹39.4 cr in FY25
Cash from financing: −₹525cr₹39.3 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	480	430	385	324
	—	−6.6	−15.2	−5.6	−4.6
	—	10.9	10.2	10.9	7.5
	—	−25.9	−1.9	−8.8	12.4
	—	−1.2	0.0	1.9	0.2
	—	7.5	−57.1	0.0	0.0
	—	−406	−82.9	−151	81.8
	—	−181	−405	−85.1	−228
	—	313	266	−88.5	−10.3
	—	24.8	−55.0	−38.5	9.9
	—	274	−98.0	334	−169
	—	0.0	0.0	−0.0	−1.0
Cash from operating activities
	1,761	1,182	484	236	1,109
	—	490	−8.4	354	23.3
	—	1,672	476	590	1,132
	—	−165	−210	−175	−145
	—	80.8	53.4	4.9	1.7
	—	294	138	105	285
	—	1,624	602	666	994
Cash from investing activities
	—	1,070	641	678	990
	—	6.8	99.9	2.3	2.7
	—	49.0	105	0.0	0.0
	—	26.7	0.0	80.0	22.3
	—	0.0	0.0	−71.6	0.0
	—	6.6	6.2	5.6	4.6
	—	43.6	−41.4	−0.4	9.2
	—	−1,089	−682	−822	−996
Cash from financing activities
	—	20.0	10.2	2.6	7.4
	—	27.7	503	758	468
	—	327	316	217	247
	—	13.5	30.9	33.3	7.8
	—	171	209	174	140
	—	86.3	43.1	86.2	107
	—	25.0	125	0.0	0.0
	—	−525	39.3	250	−26.6
	—	10.1	−40.8	93.1	−28.8
	—	3.0	1.4	0.2	−0.9
	—	13.1	−39.4	93.3	−29.7
	—	—	—	139	45.7
Reference items
	2,381	1,778	1,055	778	1,592
	30.4%	26.1%	19.0%	15.4%	26.4%
	554	554	−39.4	−12.6	3.7
	—	87.3	−62.5	348	—
	₹10.25	₹10.25	−₹0.73	−₹0.23	₹0.07
	212.79×	—	—	—	—
	—	1.82×	1.68×	4.10×	1.25×
	—	294	138	105	285
	—	171	209	174	140

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LAURUSLABS₹2,181.90

Laurus Labs Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB GLAND MANKIND BIOCON ALKEM LUPIN FORTIS GLENMARKMcap ₹1.18L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	324.1	384.6	430.1	480.1	—
+ Interest Income	-4.6	-5.6	-15.2	-6.6	—
+ Share-based Payments	7.5	10.9	10.2	10.9	—
+ Unrealised FX (Gain) / Loss	12.4	-8.8	-1.9	-25.9	—
+ Other Non-cash Items	0.2	1.9	0.0	-1.2	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	-57.1	7.5	—
Changes in Working Capital
+ Inventories	81.8	-151.3	-82.9	-405.6	—
+ Trade Receivables — Current	-227.9	-85.1	-405.0	-181.0	—
+ Other Financial Assets — Non-current	-10.3	-88.5	266.2	312.6	—
+ Other Non-current Assets	9.9	-38.5	-55.0	24.8	—
+ Trade Payables — Current	-168.9	334.4	-98.0	274.3	—
+ Provisions — Current	-1.0	-0.0	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	1,108.9	236.4	484.3	1,181.9	1,761.1
+ Total Adjustments (incl. Working Capital)	23.3	354.0	-8.4	489.9	—
Cash from Operations (pre-tax)	1,132.3	590.3	475.9	1,671.7	—
+ Interest Paid — Operating	-145.5	-175.0	-210.0	-164.9	—
+ Other Inflows / (Outflows) — Operating	1.7	4.9	53.4	80.8	—
+ Income Taxes Paid	285.5	104.6	137.5	293.9	—
Cash from Operating Activities	993.9	665.7	601.7	1,623.5	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	990.2	678.3	641.0	1,070.0	—
+ Disp of Fixed Assets	2.7	2.3	99.9	6.8	—
+ Acq of Interests in Joint Ventures	0.0	0.0	105.4	49.0	—
+ Acq of Subsidiaries / Businesses (net)	22.3	80.0	0.0	26.7	—
+ Disp of Subsidiaries / Businesses (net)	0.0	-71.6	0.0	0.0	—
+ Interest Received — Investing	4.6	5.6	6.2	6.6	—
+ Other Inflows / (Outflows) — Investing	9.2	-0.4	-41.4	43.6	—
Cash from Investing Activities	-996.1	-822.4	-681.7	-1,088.7	—
Cash from Financing Activities
+ Proceeds from Exercise of Stock Options	7.4	2.6	10.2	20.0	—
+ Proceeds from Borrowings	468.5	757.7	502.8	27.7	—
+ Repayment of Borrowings	246.8	216.7	315.7	326.9	—
+ Payment of Lease Liabilities	7.8	33.3	30.9	13.5	—
+ Interest Paid	140.4	174.3	209.2	170.7	—
+ Dividends Paid	107.5	86.2	43.1	86.3	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	125.3	25.0	—
Cash from Financing Activities	-26.6	249.8	39.3	-524.7	—
Net Changes in Cash (pre-FX)	-28.8	93.1	-40.8	10.1	—
+ Effect of FX Rate Changes on Cash	-0.9	0.2	1.4	3.0	—
Net Changes in Cash	-29.7	93.3	-39.4	13.1	—
Closing Cash	45.7	138.9	—	—	—
Reference Items
EBITDA	1,592.2	777.5	1,055.3	1,777.7	2,380.9
EBITDA Margin %	26.36	15.42	19.00	26.09	30.44
Free Cash Flow (CFO − Capex)	3.7	-12.6	-39.4	553.6	553.6
Free Cash Flow to Equity	—	348.2	-62.5	87.3	—
Free Cash Flow per Basic Share	0.07	-0.23	-0.73	10.25	10.25
Price to Free Cash Flow	—	—	—	—	212.79
Cash Flow to Net Income	1.25	4.10	1.68	1.82	—
Cash Paid for Taxes	285.5	104.6	137.5	293.9	—
Cash Paid for Interest	140.4	174.3	209.2	170.7	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.